The use of primary mesenchymal stem cells (MSCs) is fraught with ageing-related shortfalls such as limited expansion and early senescence. Human induced pluripotent stem cells (iPSCs)-derived MSCs ...
ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM EXPANSION OF IPSC DISCOVERY PLATFORM STRENGTHENS EVOTEC'S POSITION AS A ...
SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback